Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KeyForm-010
2023-505022-34-00Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial of pembrolizumab, favezelimab, lenvatinib and favezelimab + pembrolizumab in cutaneous squamous cell carcinoma (cSCC), endometrial cancer (EC) and cancer (4 cohorts), sponsored by Merck & Co. Primary endpoints: Clinical Benefit - Cohort A and Objective Response Rate (ORR) per RECIST 1.1 as assessed by Investigator – Cohort B. Started Oct 2023; status: completed.
02
Drugs
03
Conditions
cutaneous squamous cell carcinoma (cSCC)endometrial cancer (EC)cancer
Beyond the preview
Go deeper on 2023-505022-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505022-34-00.